Improving the Management of Skin and Soft Tissue Infections in Primary Care: A Report From State Networks of Colorado Ambulatory Practices and Partners (SNOCAP-USA) and the Distributed Ambulatory Research in Therapeutics Network (DARTNet)

References

1. 1.↵
   Agency for Healthcare Research and Quality (AHRQ). Medical Expenditure Panel Survey. [Web Page]. Available at http://www.meps.ahrq.gov/mepsweb/. Accessed July 23, 2010.
2. 2.↵
   1. Fridkin SK,
   2. Hageman JC,
   3. Morrison M,
   4. et al

   . Methicillin-resistant Staphylococcus aureus disease in three communities.[erratum appears in N Engl J Med 2005 June 2;352(22):2362]. N Engl J Med 2005;352:1436–44.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Tillotson GS,
   2. Draghi DC,
   3. Sahm DF,
   4. et al

   . Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005–07: laboratory-based surveillance study. J Antimicrob Chemother 2008;62:109–15. Epub 2008 April 8.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Parchman ML,
   2. Munoz A

   . Risk factors for methicillin-resistant Staphylococcal aureus skin and soft tissue infections presenting in primary care: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med 2009;22:375–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Miller LG,
   2. Perdreau-Remington F,
   3. et al

   . Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445–53.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Martinez-Aguilar G,
   2. Avalos-Mishaan A,
   3. Hulten K,
   4. et al

   . Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004;23:701–6.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Gonzalez BE,
   2. Hulten KG,
   3. Dishop MK,
   4. et al

   . Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005;41:583–90.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Hersh AL,
   2. Chambers HF,
   3. Maselli JH,
   4. Gonzales R

   . National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008;28;168:1585–91.

   OpenUrl
9. 9.↵
   1. Gorwitz RJ,
   2. Jernigan DB,
   3. Powers JH,
   4. Jernigan JA

   , and Participants in the CDC-Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at http://www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf. Accessed December 8, 2010.
10. 10.↵
    Outpatient Management of MRSA Skin and Soft Tissues Infections. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion. Available at http://www.cdc.gov/mrsa/treatment/outpatient-management.html. Accessed December 9, 2010.
11. 11.↵
    1. Liu C,
    2. Bayer A,
    3. Cosgrove SE,
    4. et al

    . Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:285–92.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Hersh AL,
    2. Cabana MD,
    3. Gonzales R,
    4. et al

    . Pediatricians' perspectives on the impact of MRSA in primary care: a qualitative study. BMC Pediatr 2009;14:9–27.

    OpenUrl
13. 13.↵
    1. Pace WD,
    2. Cifuentes M,
    3. Valuck RJ,
    4. et al

    . An electronic practice-based network for observational comparative effectiveness research. Ann Intern Med 2009;151:338–40.

    OpenUrlCrossRefPubMedWeb of Science